Sara Shama1,2, Sharon Unger1,3,4,5,6, Yves Pouliot7, Alain Doyen7, Shyam Suwal7, Paul Pencharz1,2,3, Michael A Pitino1,2, Mélanie Sergius7, Susanne Aufreiter2, Debbie Stone6, Deborah L O'Connor1,2,5,6. 1. Department of Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada. 2. Translational Medicine Program, The Hospital for Sick Children, Toronto, Ontario, Canada. 3. Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada. 4. Department of Neonatology, The Hospital for Sick Children, Toronto, Ontario, Canada. 5. Department of Pediatrics, Mount Sinai Hospital, Toronto, Ontario, Canada. 6. Rogers Hixon Ontario Human Milk Bank, Mount Sinai Hospital, Toronto, Ontario, Canada. 7. Department of Food Sciences, Institute of Nutrition and Functional Foods (INAF), Dairy Science and Technology Research Centre (STELA), Laval University, Quebec City, Quebec, Canada.
Abstract
BACKGROUND: Bovine milk-based protein modulars are currently available to nutrient-enrich enteral feedings; however, they have limitations for use in very-low-birth-weight infants. OBJECTIVES: Our objectives were to develop a human milk-based protein (HMP) concentrate and to conduct a preclinical assessment of the HMP concentrate in weanling rats. METHODS: An HMP concentrate was produced from donor milk using pressure-driven membrane filtration processes and high hydrostatic pressure processing. Protein and lactoferrin concentrations and lysozyme activity were determined by Kjeldahl, HPLC, and turbidimetric assay, respectively. Male Sprague Dawley rats 24 d old (n = 30) were randomly assigned to 1 of 3 isocaloric AIN-93G diets for 4 wk containing 100% casein (control) or with 50% of the casein replaced with the HMP concentrate (treatment) or a bovine whey protein isolate (treatment). Body weight, food intake, fat mass, plasma amino acid profiles, and organ weights were measured. Data were analyzed using linear regression models. RESULTS: Raw donor milk contained (mean ± SD) 101 ± 6 g protein/kg and 5 ± 1 g lactoferrin/kg of milk solids. Postprocessing, protein and lactoferrin concentrations were 589 ± 3 g/kg and 29 ± 10 g/kg, respectively. Lysozyme activity was initially 209 ± 4 U/kg and increased to 959 ± 39 U/kg in the HMP concentrate. There were no statistically significant differences in body weight, food intake, fat mass, or plasma amino acid profiles between rats fed diets containing the HMP concentrate and the control diet. Full cecum weights were higher in rats fed the HMP concentrate than in those fed control diets (mean difference: 5.59 g; 95% CI: 4.50, 6.68 g; P < 0.0001), likely reflecting the concentration of human milk oligosaccharides. No differences were found for other organ weights. CONCLUSIONS: The HMP concentrate retained important bioactive proteins and supported normal rat growth in the preclinical assessment.
BACKGROUND: Bovine milk-based protein modulars are currently available to nutrient-enrich enteral feedings; however, they have limitations for use in very-low-birth-weight infants. OBJECTIVES: Our objectives were to develop a human milk-based protein (HMP) concentrate and to conduct a preclinical assessment of the HMP concentrate in weanling rats. METHODS: An HMP concentrate was produced from donor milk using pressure-driven membrane filtration processes and high hydrostatic pressure processing. Protein and lactoferrin concentrations and lysozyme activity were determined by Kjeldahl, HPLC, and turbidimetric assay, respectively. Male Sprague Dawley rats 24 d old (n = 30) were randomly assigned to 1 of 3 isocaloric AIN-93G diets for 4 wk containing 100% casein (control) or with 50% of the casein replaced with the HMP concentrate (treatment) or a bovine whey protein isolate (treatment). Body weight, food intake, fat mass, plasma amino acid profiles, and organ weights were measured. Data were analyzed using linear regression models. RESULTS: Raw donor milk contained (mean ± SD) 101 ± 6 g protein/kg and 5 ± 1 g lactoferrin/kg of milk solids. Postprocessing, protein and lactoferrin concentrations were 589 ± 3 g/kg and 29 ± 10 g/kg, respectively. Lysozyme activity was initially 209 ± 4 U/kg and increased to 959 ± 39 U/kg in the HMP concentrate. There were no statistically significant differences in body weight, food intake, fat mass, or plasma amino acid profiles between rats fed diets containing the HMP concentrate and the control diet. Full cecum weights were higher in rats fed the HMP concentrate than in those fed control diets (mean difference: 5.59 g; 95% CI: 4.50, 6.68 g; P < 0.0001), likely reflecting the concentration of human milk oligosaccharides. No differences were found for other organ weights. CONCLUSIONS: The HMP concentrate retained important bioactive proteins and supported normal rat growth in the preclinical assessment.
Authors: Bonnie E Stephens; Rachel V Walden; Regina A Gargus; Richard Tucker; Leslie McKinley; Martha Mance; Julie Nye; Betty R Vohr Journal: Pediatrics Date: 2009-05 Impact factor: 7.124
Authors: P M Tomasula; S Mukhopadhyay; N Datta; A Porto-Fett; J E Call; J B Luchansky; J Renye; M Tunick Journal: J Dairy Sci Date: 2011-09 Impact factor: 4.034
Authors: Haiying Tang; Joseph R Vasselli; Ed X Wu; Carol N Boozer; Dympna Gallagher Journal: Am J Physiol Regul Integr Comp Physiol Date: 2002-03 Impact factor: 3.619
Authors: Michael P Sherman; David H Adamkin; Victoria Niklas; Paula Radmacher; Jan Sherman; Fiona Wertheimer; Karel Petrak Journal: J Pediatr Date: 2016-05-31 Impact factor: 4.406
Authors: Guido E Moro; Claude Billeaud; Buffin Rachel; Javier Calvo; Laura Cavallarin; Lukas Christen; Diana Escuder-Vieco; Antoni Gaya; David Lembo; Aleksandra Wesolowska; Sertac Arslanoglu; Debbie Barnett; Enrico Bertino; Clair-Yves Boquien; Corinna Gebauer; Anne Grovslien; Gillian A Weaver; Jean-Charles Picaud Journal: Front Pediatr Date: 2019-02-28 Impact factor: 3.418